MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
December was understandably quiet, but there was still a flurry of news from some of medtech’s biggest players. Medtronic (NYSE:MDT) maintained its spot at the top of the internet chatter pyramid with news of its ground-breaking brain-monitoring implant as well as several other technologies.
Johnson & Johnson‘s (NYSE:JNJ) was mostly out of the limelight, but took 2nd place for with its Ethicon subsidiary inspiring a few headlines with legal scandals and an FDA win.
Covidien (NYSE:COV) made it to 3rd place, announcing the $860 million buyout of Given Imaging after lowering its own sales guidance and revising its reporting policies. St. Jude Medical (NYSE:STJ) got a lot of attention after halting its renal denervation clinical trial. The company also released news from neurostimulation trials and hit high after high on Wall Street.
Boston Scientific (NYSE:BSX) rounded out the top 5 with stories of its plans for China, a few regulatory wins and questions about its Watchman cardiac implant.
Medtronic
- Medtronic exec questions CardioMEMS Champion
- Medtronic implants 1st U.S. patients with new brain-monitoring stimulation implant
- Medtronic’s ‘brain pacemaker’ and the future of neurological disease treatment
- Medtronic touts E.U., Aussie wins for next-gen Symplicity renal denervation components
- Study: Medtronic’s Prestige spinal disc replacement beats fusion in 7-year results
- Medtronic aims to disrupt with pill-sized cardiac pacemaker
- Medtronic slips $18M verdict in surgical fire case
- Medtronic’s new renal denervation trial examines less-severe hypertension
- NuVasive’s new European teammates come from Medtronic, DePuy
- Medtronic to invest $6M, create 150 jobs in Puerto Rico expansion
Johnson & Johnson
- Pelvic mesh plaintiffs accuse Ethicon of destroying evidence
- J&J’s Ethicon pays $1.3M FDA settlement over mislabeled products
- Ethicon wins FDA clearance for surgical shears
Covidien
- Medtech M&A: Covidien’s $860M buyout sends Given Imaging’s stock soaring
- Covidien revises reporting structure, lowers sales guidance
St. Jude Medical
- St. Jude Medical wins CE Mark for larger Portico heart valve
- Federal court rejects St. Jude’s appeal in infringement case against AccessClosure
- St. Jude Medical halts Enlightn IV trial
- St. Jude to buy back $700M in outstanding shares, affirms outlook
- St. Jude Medical launches another neurostim trial, hits 52-week high
- St. Jude Medical launches Prodigy neurostim trial for chronic pain
Boston Scientific
- Boston Scientific puts more skin in China
- Boston Scientific wins CE Mark for X4 quadripolar defibrillator line
- FDA panel OKs Boston Scientific’s Watchman anti-stroke implant
- Boston Scientific’s Watchman anti-stroke implant wins over FDA panel
- Vascular Solutions claims a win against Boston Scientific
- Boston Scientific faces more questions over Watchman implant’s effectiveness, risks
- Boston Scientific touts high success rate, pain reduction with Precision Spectra spinal cord stim
- Boston Scientific inks co-promotion deal for Promus Premier stent